8-K: Clene Reports 2025 Results, Eyes FDA Approval for ALS Drug

Clene Inc. announced its full year 2025 financial results and provided updates on its CNM-Au8 programs, including an upcoming FDA meeting for ALS accelerated approval pathway.

Summary

• Clene reported a net loss of $26.2 million for the full year ended December 31, 2025, an improvement from a net loss of $39.4 million in 2024.
• Cash and cash equivalents totaled $5.2 million as of December 31, 2025, down from $12.2 million as of December 31, 2024.
• The company completed an oversubscribed registered direct offering of over $28 million, priced above market, in January 2026.
• An initial tranche of over $6 million from the offering provides operating cash runway to the end of the third quarter of 2026, covering a potential NDA acceptance decision by the FDA.
• Two potential additional financing tranches totaling over $22 million are structured to align with NDA acceptance and FDA approval milestones, expected to provide capital into 2027.
• A Type C face-to-face meeting with the FDA is scheduled by the end of the first quarter of 2026 to discuss CNM-Au8 biomarker and survival data for ALS.
• Formal written meeting minutes from the FDA are expected early in the second quarter of 2026, after which the outcome will be publicly announced.
• Clene plans to file a New Drug Application (NDA) for CNM-Au8 in ALS under an accelerated approval pathway by the end of the second quarter of 2026.
• Biomarker analyses completed in December 2025 demonstrated statistically significant reductions in neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP), correlating to improved survival in ALS patients.
• CNM-Au8 has a favorable safety profile across over 1,100 patient years of exposure, with no significant safety concerns or serious adverse events identified.
• Research and development expenses decreased to $14.0 million in 2025 from $20.1 million in 2024, primarily due to trial completions and increased grant revenue.
• General and administrative expenses decreased to $9.2 million in 2025 from $13.3 million in 2024, driven by lower fees and increased grant revenue.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive update, driven by significant progress in clinical development for CNM-Au8, positive biomarker data, and a successful financing round that extends the cash runway, despite ongoing net losses.

Positives

• Net loss significantly decreased to $26.2 million in 2025 from $39.4 million in 2024.
• Research and development expenses decreased by $6.1 million year-over-year to $14.0 million in 2025.
• General and administrative expenses decreased by $4.1 million year-over-year to $9.2 million in 2025.
• Successfully completed an oversubscribed registered direct offering of over $28 million, priced above market.
• Initial financing tranche of over $6 million provides cash runway to the end of Q3 2026, covering potential FDA NDA acceptance.
• Potential for additional $22 million in financing tranches to extend cash runway into 2027.
• Positive biomarker data for CNM-Au8 in ALS, showing statistically significant reductions in NfL and GFAP, which correlated to improved survival.
• Favorable safety profile for CNM-Au8 with no significant safety concerns or serious adverse events identified over 1,100 patient years of exposure.
• Upcoming Type C FDA meeting and planned NDA submission for accelerated approval pathway in ALS represent significant clinical milestones.

Negatives

• Cash and cash equivalents decreased to $5.2 million as of December 31, 2025, from $12.2 million as of December 31, 2024.
• The company continues to operate at a net loss of $26.2 million for the full year 2025.
• Total stockholders deficit increased to $(17.592) million in 2025 from $(8.857) million in 2024.

Risks

• General market conditions could impact future performance and financing capabilities.
• Clinical trials may not demonstrate the efficacy and safety of drug candidates to the satisfaction of regulatory authorities.
• Clinical results for drug candidates may not support further development or marketing approval.
• Actions of regulatory agencies (e.g., FDA) may affect the initiation, timing, and progress of clinical trials and marketing approval.
• The company's ability to achieve commercial success for its drug candidates, if approved, is uncertain.
• Limited operating history and the ability to obtain additional funding for operations and to complete the development and commercialization of drug candidates.
• Forward-looking statements involve judgments, risks, and uncertainties, and actual results or performance may materially differ from those expressed or implied.

Future Outlook

The company anticipates a Type C FDA meeting by the end of Q1 2026, with formal minutes expected early in Q2 2026. Following this, they plan to file an NDA for CNM-Au8 in ALS under an accelerated approval pathway by the end of Q2 2026. In parallel, plans are advancing to initiate a confirmatory Phase 3 trial in ALS and to work with the FDA on a Phase 3 clinical trial for MS using cognition as an endpoint. The recently secured financing is expected to provide cash runway into 2027.

Management Comments

• "Our next key milestone is the upcoming Type C face-to-face meeting with the U.S. Food and Drug Administration (FDA) on Clene's biomarker and survival data, which if positive, will facilitate filing of an new drug application (NDA) under an accelerated approval pathway for ALS by the end of the second quarter of 2026."
• "In parallel, we continue to advance plans to initiate our confirmatory Phase 3 trial in ALS, which is required to be underway by CNM-Au8 approval in ALS, as well as to continue working with the FDA on the initiation of a Phase 3 clinical trial using cognition as an endpoint in MS."
• "Based on our combined findings to date, we continue to believe that patients across multiple neurodegenerative conditions may benefit from the improved mitochondrial function plus energy metabolism associated with CNM-Au8 treatment."

Industry Context

StockSavvy.ai notes that the biopharmaceutical sector, particularly in neurodegenerative diseases like ALS and MS, faces significant R&D costs and regulatory hurdles. Successful biomarker data and a clear path to an FDA meeting for accelerated approval, as seen with Clene, are critical milestones that can differentiate a company in this highly competitive and challenging therapeutic area. The focus on mitochondrial health and the NAD pathway represents an innovative approach within the field.

Comparison to Industry Standards

• StockSavvy.ai observes that the reduction in net loss from $39.4 million to $26.2 million, alongside decreased R&D and G&A expenses, indicates improved cost management, which is crucial for clinical-stage biotechs often operating at a loss.
• The successful oversubscribed registered direct offering, priced above market, suggests strong investor confidence, which is a positive signal compared to many smaller biotechs that struggle with dilutive financing at lower valuations.
• The biomarker data showing statistically significant reductions in NfL and GFAP, correlating to improved survival in ALS, aligns with the high bar set by regulatory bodies for neurodegenerative disease treatments. For example, Amylyx Pharmaceuticals' Relyvrio for ALS also received accelerated approval based on a single trial and survival benefit, setting a precedent that Clene aims to follow.
• The safety profile of CNM-Au8, with no significant safety concerns over 1,100 patient years, is a strong point, especially when compared to other neurodegenerative drugs that often come with significant side effects.

Stakeholder Impact

• Shareholders: Potential for significant value creation if CNM-Au8 receives accelerated approval and subsequent commercial success. Dilution from the registered direct offering is a factor, but the above-market pricing mitigates some concerns.
• Patients (ALS/MS): Hope for a new treatment option with a favorable safety profile and evidence of biomarker decline correlating to improved survival.
• Employees: Continued employment and potential growth opportunities if the drug progresses to market.
• Creditors: Improved financial stability and extended cash runway reduce immediate solvency concerns.

Next Steps

• Type C FDA meeting by end of Q1 2026.
• Await formal written FDA meeting minutes early in Q2 2026.
• Publicly announce the outcome of the FDA meeting after receiving minutes.
• File an NDA for CNM-Au8 in ALS under an accelerated approval pathway by the end of Q2 2026.
• Initiate a confirmatory Phase 3 trial in ALS.
• Continue working with the FDA on initiating a Phase 3 clinical trial using cognition as an endpoint in MS.
• Receive additional financing tranches totaling over $22 million upon NDA acceptance and FDA approval milestones.

Key Dates

Recommendation

The company has made substantial progress with its CNM-Au8 program, including positive biomarker data, a clear path to an FDA meeting for accelerated approval in ALS, and a successful financing round that extends its cash runway. These are strong indicators of potential future success. However, the company remains unprofitable, and significant regulatory hurdles and commercialization challenges still lie ahead. The 'hold' recommendation acknowledges the positive momentum and potential upside while recognizing the inherent risks and the need for further validation through FDA approval and successful market entry.

Keywords

ALS, Multiple Sclerosis, Neurodegenerative Diseases, CNM-Au8, FDA, NDA, Biopharmaceutical, Clinical-stage, Mitochondrial Health, Neuronal Function, Biomarker, NfL, GFAP, Accelerated Approval, Financing, Registered Direct Offering, Clinical Trial, Phase 3, Financial Results